Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Keyvian
Emeryville, California, United Statesreddit.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Kyverna is a clinical-stage biopharmaceutical company developing CAR-T cell therapies for autoimmune diseases. Its lead program KYV-101 targets CD19 and has advanced into multiple clinical trials for lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis. Early results in oncology suggest safety; current studies are focused on efficacy in autoimmune indications. The company also collaborates with Intellia Therapeutics on an off-the-shelf allogeneic CAR-T candidate.
- Therapeutic areas
- RheumatologyImmunologyNeurology
- Modalities
- CAR-T cell therapyCell therapy
- Industry
- Biotech
02
Partnerships
Intellia Therapeutics (for gene-edited allogeneic program)
Beyond the preview
Go deeper on Keyvian.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Keyvian.